#metabolic dysfunction
Discover 2 curated intelligence briefings related to this specific topic.
Health & Medicine
The Liver Pivot: Semaglutide’s New Frontier in Fibrosis
The global conversation around Semaglutide is shifting. No longer just a tool for weight loss or glycemic control, the metabolic powerhouse is now being targeted at the stubborn architecture of liver fibrosis, marking a strategic pivot in how we treat metabolic dysfunction-associated steatohepatitis (MASH).
Read Analysis
Health & Medicine
Semaglutide Just Targeted the Liver's Deadliest Scarring
Recent Phase II data reveals semaglutide's ability to reduce liver scarring in patients with MASH, while Novo Nordisk bets billions on new delivery platforms to ensure long-term organ preservation.
Read Analysis